EW Stock Forecast 2025-2026
Distance to EW Price Targets
EW Price Momentum
10 Quality Stocks Worth Considering Now
Researching Edwards Lifesciences (EW) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EW and similar high-potential opportunities.
Latest EW Stock Price Targets & Analyst Predictions
Based on our analysis of 37 Wall Street analysts, EW has a neutral consensus with a median price target of $80.00 (ranging from $61.00 to $96.80). The overall analyst rating is Buy (7.4/10). Currently trading at $71.09, the median forecast implies a 12.5% upside. This outlook is supported by 15 Buy, 17 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EW Analyst Ratings
EW Price Target Range
Latest EW Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EW.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $90.00 |
| Feb 13, 2025 | Canaccord Genuity | William Plovanic | Hold | Maintains | $71.00 |
| Feb 12, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $73.00 |
| Feb 12, 2025 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $73.00 |
| Feb 12, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $75.00 |
| Feb 12, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $85.00 |
| Jan 30, 2025 | Stifel | Rick Wise | Buy | Upgrade | $90.00 |
| Jan 16, 2025 | Wolfe Research | Mike Polark | Underperform | Downgrade | $60.00 |
| Dec 16, 2024 | B of A Securities | Travis Steed | Buy | Upgrade | $90.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $83.00 |
| Dec 5, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $85.00 |
| Dec 5, 2024 | Canaccord Genuity | William Plovanic | Hold | Maintains | $68.00 |
| Dec 5, 2024 | Stifel | Rick Wise | Hold | Maintains | $75.00 |
| Dec 5, 2024 | Truist Securities | Richard Newitter | Hold | Reiterates | $78.00 |
| Dec 5, 2024 | Goldman Sachs | David Roman | Buy | Maintains | $90.00 |
| Dec 2, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $88.00 |
| Nov 27, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $80.00 |
| Oct 25, 2024 | Baird | David Rescott | Neutral | Maintains | $68.00 |
| Oct 25, 2024 | Canaccord Genuity | William Plovanic | Hold | Maintains | $63.00 |
| Oct 25, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $70.00 |
Edwards Lifesciences Corporation (EW) Competitors
The following stocks are similar to Edwards Lifesciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Edwards Lifesciences Corporation (EW) Financial Data
Edwards Lifesciences Corporation has a market capitalization of $41.79B with a P/E ratio of 30.4x. The company generates $5.44B in trailing twelve-month revenue with a 76.7% profit margin.
Revenue growth is +9.4% quarter-over-quarter, while maintaining an operating margin of +25.5% and return on equity of +16.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Edwards Lifesciences Corporation (EW) Business Model
About Edwards Lifesciences Corporation
Develops innovative medical devices for cardiovascular conditions.
Edwards Lifesciences generates revenue through the sale of heart valve products and hemodynamic monitoring systems. By focusing on innovative solutions like transcatheter aortic valve replacement (TAVR), the company meets critical healthcare needs and collaborates with professionals to ensure its products are effective and widely adopted.
Headquartered in Irvine, California, Edwards Lifesciences is a leader in a competitive market characterized by rapid technological advancements and a strong emphasis on improving patient outcomes. The company is pivotal in setting industry standards for cardiovascular care.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
15,800
CEO
Mr. Bernard J. Zovighian
Country
United States
IPO Year
2000
Website
www.edwards.comEdwards Lifesciences Corporation (EW) Latest News & Analysis
In 2025, Health Care and Energy sectors excel, with the Health Care Select Sector SPDR ETF up 7% YTD. Edwards Lifesciences lags despite a strong Q4, with a target price of $84 and risks in TAVR growth.
The Health Care sector's strong performance contrasts with Edwards Lifesciences' undervaluation, suggesting potential for upside if growth concerns stabilize, impacting investment decisions.
Intuitive Ventures appointed Terri Burke as Senior Partner and Dr. Ross Jaffe as Venture Advisor to enhance its focus on investing in minimally invasive care startups.
The appointment of experienced medtech leaders enhances Intuitive Ventures' credibility and expertise, potentially leading to successful investments and increased returns in the growing minimally invasive care sector.
Edwards Lifesciences (NYSE: EW) will present at the TD Cowen Health Care Conference on March 4, 2025, at 9:50 a.m. ET. A live and archived webcast will be available on their investor relations site.
Edwards Lifesciences' participation in a major health care conference highlights its strategic positioning and potential growth, impacting investor sentiment and stock performance.
EW stock attracts investor attention due to potential in structural heart opportunities after divesting its Critical Care segment.
EW's focus on structural heart opportunities post-divestment enhances growth potential, making it an attractive option for investors seeking innovation in the healthcare sector.
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
1 month agoEdwards Lifesciences reported Q4 sales of $1.39 billion, exceeding expectations of $1.36 billion, with a 9% year-over-year growth across all product groups.
Edwards Lifesciences' Q4 sales beat expectations, showing 9% growth across all product segments, indicating strong demand and potential for continued profitability, which can boost investor confidence.
Edwards Lifesciences reports strong performance across all product groups, including TAVR, TTMT, and surgical structural heart products.
Strong performance across all product lines indicates robust demand and potential revenue growth for Edwards Lifesciences, positively impacting investor sentiment and stock performance.
Frequently Asked Questions About EW Stock
What is Edwards Lifesciences Corporation's (EW) stock forecast for 2025?
Based on our analysis of 37 Wall Street analysts, Edwards Lifesciences Corporation (EW) has a median price target of $80.00. The highest price target is $96.80 and the lowest is $61.00.
Is EW stock a good investment in 2025?
According to current analyst ratings, EW has 15 Buy ratings, 17 Hold ratings, and 1 Sell ratings. The stock is currently trading at $71.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EW stock?
Wall Street analysts predict EW stock could reach $80.00 in the next 12 months. This represents a 12.5% increase from the current price of $71.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Edwards Lifesciences Corporation's business model?
Edwards Lifesciences generates revenue through the sale of heart valve products and hemodynamic monitoring systems. By focusing on innovative solutions like transcatheter aortic valve replacement (TAVR), the company meets critical healthcare needs and collaborates with professionals to ensure its products are effective and widely adopted.
What is the highest forecasted price for EW Edwards Lifesciences Corporation?
The highest price target for EW is $96.80 from at , which represents a 36.2% increase from the current price of $71.09.
What is the lowest forecasted price for EW Edwards Lifesciences Corporation?
The lowest price target for EW is $61.00 from at , which represents a -14.2% decrease from the current price of $71.09.
What is the overall EW consensus from analysts for Edwards Lifesciences Corporation?
The overall analyst consensus for EW is neutral. Out of 37 Wall Street analysts, 15 rate it as Buy, 17 as Hold, and 1 as Sell, with a median price target of $80.00.
How accurate are EW stock price projections?
Stock price projections, including those for Edwards Lifesciences Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
